Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Petosemtamab · MCLA-158, GEN1158

Bispecific antibody · Antagonist of epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) · developed by Genmab

Phase 3 Most advanced trial
GMAB Developer
2 Registered trials

What is Petosemtamab?

Petosemtamab is an IgG1 bispecific antibody that binds both EGFR and LGR5, inhibiting signaling through both receptors and thereby tumor cell proliferation. It is being studied in solid tumors including colorectal cancer, gastric and gastroesophageal-junction cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, alone or in combination with chemotherapy or pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MCLA-158, GEN1158
Drug type
Bispecific antibody
Targets
epidermal growth factor receptor (EGFR), leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)
Mechanism
Antagonist of epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)
Pathways
EGFR signaling, Wnt signaling, tumor cell proliferation
Therapy area
Oncology
Developer
Genmab (GMAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
Z6Z6IVE7W4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06525220 Phase 3 Head and Neck Squamous Cell Carcinoma Active not recruiting GMAB
NCT03526835 Phase 1/2 Advanced/Metastatic Solid Tumors Recruiting GMAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced/Metastatic Solid TumorsColorectal CancerEsophageal CancerGastric CancerGastroesophageal-junction CancerHead and Neck Squamous Cell CarcinomaHNSCCNSCLC

Other drugs acting on EGFR / LGR5

More from Genmab

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.

Follow GMAB, the company behind Petosemtamab

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.